Private investors led the funding for the Cardiff-by-the-Sea, California-based cardiac ablation technology developer. Multiple strategic investors also joined the round. The company earmarked the funds to support preclinical-to-clinical development activities. That includes first-in-human studies slated to begin in early 2024.
Field Medical was founded last year by Dr. Steven Mickelsen, the founder of Farapulse. Mickelsen also serves as CEO. He led his previous pulsed-field ablation (PFA) technology developer to an acquisition worth at least $460 million by Boston Scientific in 2021. Boston Scientific recently shared positive updates on that Farapulse technology, which Field Medical could eventually look to rival.
The company’s core products, the FieldForce Catheter and FieldForc…